1. 1) Fleisch H. Diphosphonates: history and mechanisms of actions. Metab. Bone Dis. Relat. Res., 3, 279–287 (1981).
2. 2) Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg., 61, 1115–1117 (2003).
3. 3) Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J. Clin. Oncol., 21, 4253–4254 (2003).
4. 4) Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int. J. Oral Maxillofac. Surg., 44, 568–585 (2015).
5. 5) Geddes AD, D’Souza SM, Ebetino FH, Kenneth JI. Bisphosphonates: structure–activity relationships and therapeutic implications. Bone and Mineral Research (Heershe NM, Kanis JK ed.) Vol. 8, Elsevier Science BV, Amsterdam, Holland, pp. 265–306 (1994).